Killer Cells, Lymphokine-Activated
"Killer Cells, Lymphokine-Activated" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.
Descriptor ID |
D015979
|
MeSH Number(s) |
A11.118.637.555.283.500 A11.118.637.555.567.537.500 A15.145.229.637.555.283.500 A15.145.229.637.555.567.537.500 A15.382.490.555.283.500 A15.382.490.555.567.537.500
|
Concept/Terms |
Killer Cells, Lymphokine-Activated- Killer Cells, Lymphokine-Activated
- Cell, Lymphokine-Activated Killer
- Cells, Lymphokine-Activated Killer
- Killer Cell, Lymphokine-Activated
- Killer Cells, Lymphokine Activated
- Lymphokine-Activated Killer Cell
- Lymphokine-Activated Killer Cells
- Lymphokine Activated Killer Cells
- LAK Cells
- Cell, LAK
- Cells, LAK
- LAK Cell
|
Below are MeSH descriptors whose meaning is more general than "Killer Cells, Lymphokine-Activated".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Cytokine-Induced Killer Cells [A11.118.637.555.283]
- Killer Cells, Lymphokine-Activated [A11.118.637.555.283.500]
- Lymphocytes [A11.118.637.555.567]
- Killer Cells, Natural [A11.118.637.555.567.537]
- Killer Cells, Lymphokine-Activated [A11.118.637.555.567.537.500]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Cytokine-Induced Killer Cells [A15.145.229.637.555.283]
- Killer Cells, Lymphokine-Activated [A15.145.229.637.555.283.500]
- Lymphocytes [A15.145.229.637.555.567]
- Killer Cells, Natural [A15.145.229.637.555.567.537]
- Killer Cells, Lymphokine-Activated [A15.145.229.637.555.567.537.500]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Cytokine-Induced Killer Cells [A15.382.490.555.283]
- Killer Cells, Lymphokine-Activated [A15.382.490.555.283.500]
- Lymphocytes [A15.382.490.555.567]
- Killer Cells, Natural [A15.382.490.555.567.537]
- Killer Cells, Lymphokine-Activated [A15.382.490.555.567.537.500]
Below are MeSH descriptors whose meaning is more specific than "Killer Cells, Lymphokine-Activated".
This graph shows the total number of publications written about "Killer Cells, Lymphokine-Activated" by people in this website by year, and whether "Killer Cells, Lymphokine-Activated" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 1 | 0 | 1 |
2001 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Killer Cells, Lymphokine-Activated" by people in Profiles.
-
Tario JD, Muirhead KA, Pan D, Munson ME, Wallace PK. Tracking immune cell proliferation and cytotoxic potential using flow cytometry. Methods Mol Biol. 2011; 699:119-64.
-
Morecki S, Gelfand Y, Nagler A, Or R, Naparstek E, Varadi G, Engelhard D, Akerstein A, Slavin S. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant. 2001 Aug; 28(3):243-9.
-
Harris DT, Sakiestewa D, Robledo RF, Young RS, Witten M. Effects of short-term JP-8 jet fuel exposure on cell-mediated immunity. Toxicol Ind Health. 2000 Feb; 16(2):78-84.
-
Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999 Aug; 155(2):537-47.
-
Harris DT. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant. 1995 Jan; 15(1):17-23.
-
Kapur R, Evans DL, Harris DT. Evolutionary conservation of a human function-associated molecule on murine natural killer cells: expression and function. Scand J Immunol. 1994 Jul; 40(1):50-6.
-
Harris DT, Camenisch TD, Jaso-Friedmann L, Evans DL. Expression of an evolutionarily conserved function associated molecule on sheep, horse and cattle natural killer cells. Vet Immunol Immunopathol. 1993 Oct; 38(3-4):273-82.
-
Gaspari AA, Fleisher TA, Kraemer KH. Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum. J Clin Invest. 1993 Sep; 92(3):1135-42.
-
Gomella LG, Ehya H, Steinberg SM, Rupp M, Merino M, Robertson C, Linehan WM. Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. J Surg Oncol. 1993 Aug; 53(4):252-5.
-
Yeung RS, Vollmer C, Taylor DD, Palazzo J, Weese JL. Intratumoral rIL2-based immunotherapy in B16 melanoma. J Surg Res. 1992 Aug; 53(2):203-10.